US › Healthcare

CervoMed Inc. (CRVO)

US · Healthcare · Biotechnology

$2.24-0.44%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-6.6M

EPS

$-0.64

EPS estimate

$-0.87

EPS came in at -0.64 against a street estimate of -0.87 — a beat of 26.4%.

Key statistics

Market cap

$34.6M

Forward P/E

0.0

P/B

1.67

Book value

$1.70

EPS (TTM)

$-3.27

52-week high

$10.00

52-week low

$2.13

50-day MA

$2.70

200-day MA

$3.84

Beta

-4.30

Analyst view

Analysts rate CervoMed Inc. a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $15.40.

Shareholding

Insiders

26.43%

Institutions

22.28%

Largest institutional holders

Fund	Stake
Morgan Stanley - Brokerage Accounts	4.89%
Woodline Partners LP	4.56%
Vanguard Capital Management, LLC	2.09%
Sabby Management LLC	1.65%
Geode Capital Management, LLC	0.44%
BlackRock Inc	0.36%
Byrne Asset Management LLC	0.34%
Citizens Financial Group Inc	0.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CervoMed Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.